drugset / Trial / NCT01178099

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

NCT01178099

Phase 1 Completed 26 enrolled Eli Lilly and Company Daiichi Sankyo · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).

Timeline

Start
2010-07
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Prasugrel Small molecule 5 mg Oral
Subject Prasugrel Small molecule 7.5 mg Oral

Indications